

18 FEBRUARY 2022

LGP WINS ITALIAN TENDER

ASX ANNOUNCEMENT

Highlights:

- 🌿 LGP awarded Government tender for medicinal cannabis flower from its Danish Facility into Italy
- 🌿 Italian Government tenders the sole route into Italian flower market, with tender quality standards some of the highest globally and LGP one of only two suppliers to bid for tender
- 🌿 Award builds on Company's growing European market momentum as LGP joins small group of international cannabis producers qualified to supply cannabis flower medicines into Italy
- 🌿 Tender award grants LGP access to Italian market with 60 million population and Total Addressable Market of A\$10 billion

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce the award of an Italian Government tender to deliver a shipment of EU GMP medicinal cannabis flower from its Danish Facility into Italy.

The shipment value of ~€200,000 is not material, however with the award LGP has joined a small group of international cannabis producers qualified to supply cannabis flower medicines into Italy, positioning LGP strongly for future upcoming Italian Government tenders. Italy has a population of 60 million people and a Total Addressable Market estimated at ~A\$10 billion.

Italian Government tenders impose some of the highest GMP product quality standards globally, with LGP one of only two suppliers bidding for the tender and with only Aurora having been successful in the past. The shipment will be of historic inventory acquired as part of LGP's purchase of its Danish Facility from Canopy Growth.

The Italian award builds on LGP's growing momentum in European and UK markets, with LGP now having supplied products into Germany, France, the UK and Denmark as it also continues to progress product registration pathways into Greece and Poland.





Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 00500

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² EU GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and AU GMP manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

